SCHEMBL8248238

SCHEMBL8248238

O=C(Cc1ccc(NS(=O)(=O)c2ccc3ccccc3c2)cc1)NO

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.71
HDAC8 Q9BY41 4/20 0.71
LMNA P02545 4/20 0.61
ALDH1A1 P00352 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
GAA P10253 2/20 0.61
ATM Q13315 1/20 0.59
PGR P06401 1/20 0.56
HDAC4 P56524 2/20 0.56
HDAC3 O15379 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56
HDAC11 Q96DB2 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HDAC9 Q9UKV0 1/20 0.56
HDAC5 Q9UQL6 1/20 0.56
PLAU P00749 2/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14812106 0.84 HDAC8 (1.00) HDAC1HDAC8LMNAALDH1A1HDAC4
SCHEMBL27768734 0.82 HDAC8 (0.67) HDAC1HDAC8LMNAALDH1A1SMN1; SMN2
SCHEMBL2690605 0.81 HDAC1 (0.65) HDAC1HDAC8LMNAALDH1A1PGR
SCHEMBL15480550 0.80 LMNA (0.73) HDAC1HDAC8LMNAALDH1A1SMN1; SMN2
SCHEMBL2691322 0.80 HDAC1 (0.76) HDAC1HDAC8LMNAALDH1A1SMN1; SMN2
SCHEMBL2691033 0.79 HDAC1 (0.74) HDAC1HDAC8LMNAALDH1A1SMN1; SMN2
SCHEMBL3563084 0.79 SLC16A3 (0.75) HDAC1HDAC8LMNAALDH1A1SMN1; SMN2
SCHEMBL15444481 0.79 HDAC8 (0.70) HDAC1HDAC8LMNAALDH1A1PGR
SCHEMBL2690294 0.78 KMT2A (0.67) HDAC1HDAC8ALDH1A1SMN1; SMN2GAA
SCHEMBL20021984 0.78 ATM (0.72) HDAC1LMNAALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2014-01-23 US disclosed
EP-2573069-A2 Inhibitors of histone deacetylase and prodrugs thereof MethylGene Inc. (CA) 2013-03-27 EP disclosed
US-RE43343-E1 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-05-01 US disclosed
WO-2008074132-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-26 WO disclosed
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-19 US disclosed
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-19 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC8 9/4885LMNA 1585/4885
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC8 9/4885LMNA 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.